INTRODUCTION: There is little robust empirical evidence on which to base treatment recommendations for fatty acid oxidation disorders. While consensus guidelines are important, understanding areas where there is a lack of consensus is also critical to inform priorities for future evaluative research. METHODS: We surveyed Canadian metabolic physicians on the treatment of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, and mitochondrial trifunctional protein (MTP) deficiency. We ascertained physicians' opinions on the use of different interventions for the long-term management of patients as well as for the management of acute illness, focusing on identifying interventions characterized by high variability in opinions. We also investigated factors influencing treatment decisions. RESULTS: We received 18 responses (response rate 45%). Participants focused on avoidance of fasting and increased meal frequency as interventions for the management of MCAD deficiency. For the long-chain disorders, avoidance of fasting remained the most consistently endorsed intervention, with additional highly endorsed treatments differing for VLCAD versus LCHAD/MTP deficiency. L-carnitine supplementation and restriction of dietary fat were characterized by high variability in physicians' opinions, as were several interventions specific to long-chain disorders. Social factors and patient characteristics were important influences on treatment decisions. CONCLUSIONS: Based on our findings we suggest that high priority treatments for rigorous effectiveness studies could include L-carnitine supplementation (MCAD and LCHAD/MTP deficiencies), restriction of dietary fat, and, for the long-chain disorders, feeding practices for breastfed infants and the use of various supplements (essential fatty acids, carbohydrates, cornstarch, multivitamins).
INTRODUCTION: There is little robust empirical evidence on which to base treatment recommendations for fatty acidoxidation disorders. While consensus guidelines are important, understanding areas where there is a lack of consensus is also critical to inform priorities for future evaluative research. METHODS: We surveyed Canadian metabolic physicians on the treatment of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, and mitochondrial trifunctional protein (MTP) deficiency. We ascertained physicians' opinions on the use of different interventions for the long-term management of patients as well as for the management of acute illness, focusing on identifying interventions characterized by high variability in opinions. We also investigated factors influencing treatment decisions. RESULTS: We received 18 responses (response rate 45%). Participants focused on avoidance of fasting and increased meal frequency as interventions for the management of MCAD deficiency. For the long-chain disorders, avoidance of fasting remained the most consistently endorsed intervention, with additional highly endorsed treatments differing for VLCAD versus LCHAD/MTP deficiency. L-carnitine supplementation and restriction of dietary fat were characterized by high variability in physicians' opinions, as were several interventions specific to long-chain disorders. Social factors and patient characteristics were important influences on treatment decisions. CONCLUSIONS: Based on our findings we suggest that high priority treatments for rigorous effectiveness studies could include L-carnitine supplementation (MCAD and LCHAD/MTP deficiencies), restriction of dietary fat, and, for the long-chain disorders, feeding practices for breastfed infants and the use of various supplements (essential fatty acids, carbohydrates, cornstarch, multivitamins).
Authors: Robert C Griggs; Mark Batshaw; Mary Dunkle; Rashmi Gopal-Srivastava; Edward Kaye; Jeffrey Krischer; Tan Nguyen; Kathleen Paulus; Peter A Merkel Journal: Mol Genet Metab Date: 2008-11-13 Impact factor: 4.797
Authors: Alex R Kemper; Coleen A Boyle; Javier Aceves; Denise Dougherty; James Figge; Jill L Fisch; Alan R Hinman; Carol L Greene; Christopher A Kus; Julie Miller; Derek Robertson; Joseph Telfair; Brad Therrell; Michele Lloyd-Puryear; Peter C van Dyck; R Rodney Howell Journal: Genet Med Date: 2008-04 Impact factor: 8.822
Authors: C Bieneck Haglind; A Nordenström; S Ask; U von Döbeln; J Gustafsson; M Halldin Stenlid Journal: J Inherit Metab Dis Date: 2014-08-21 Impact factor: 4.982
Authors: Melanie B Gillingham; Cary O Harding; Dale A Schoeller; Dietrich Matern; Jonathan Q Purnell Journal: Am J Physiol Endocrinol Metab Date: 2013-09-24 Impact factor: 4.310
Authors: Beth K Potter; Pranesh Chakraborty; Jonathan B Kronick; Kumanan Wilson; Doug Coyle; Annette Feigenbaum; Michael T Geraghty; Maria D Karaceper; Julian Little; Aizeddin Mhanni; John J Mitchell; Komudi Siriwardena; Brenda J Wilson; Ania Syrowatka Journal: Genet Med Date: 2012-12-06 Impact factor: 8.822